Kenneth Haft, MD
Pulmonary Disease · Richmond, VANPI 1972529717
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (34.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 48.0% of the total. Reporting peaked in 2024 at $3,806 and has fallen 87.1% since, to $493 in 2025.
Across 140 payments — averaging $53.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Paratek Pharmaceuticals, Inc.$1K
- Actelion Pharmaceuticals, Ltd$669
- GSK$434
- Amgen$220
- AstraZeneca$201
- plus $1K from 25 others
Across 8 payments — averaging $4578.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$34K
- GSK$3K
What the payments were for
- Consulting fees$1,16016%
- Travel & lodging$1,48320%
- Food & beverage$2,27030%
- Education$2,53434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,575 |
| Paratek Pharmaceuticals, Inc. | 3 | $1,186 |
| Actelion Pharmaceuticals, Ltd | 9 | $669 |
| GSK | 35 | $434 |
| Amgen | 11 | $220 |
| AstraZeneca | 7 | $201 |
| Insmed, Inc. | 10 | $139 |
| Sanofi | 8 | $134 |
| Grifols USA, LLC | 6 | $116 |
| Vifor Pharma, Inc. | 5 | $93 |
| Boehringer Ingelheim | 6 | $92 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| Genentech USA, Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| Philips North America LLC | 2 | $31 |
| Mylan Specialty L.p. | 2 | $26 |
| Covidien LP | 2 | $26 |
| Atricure, Inc. | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $19 |
| Gilead | 1 | $18 |
| Novartis | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| United Therapeutics Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Sandoz | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,476
- NUZYRA$1,160
- BREZTRI$100
How this compares
$7,446 in reported general payments places this provider in the 70th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 493 | $480,752 |
| Spiriva RespimatTiotropium Bromide | 156 | $145,954 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $118,204 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $105,405 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $91,010 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 111 | $86,344 |
| XareltoRivaroxaban | 51 | $51,274 |
| Spiriva HandihalerTiotropium Bromide | 49 | $49,612 |
| SymbicortBudesonide/Formoterol Fumarate | 98 | $39,347 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $34,366 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 150 | $23,687 |
| Wixela InhubFluticasone Propion/Salmeterol | 158 | $22,975 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 740 | $19,150 |
| Arnuity ElliptaFluticasone Furoate | 44 | $16,313 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $14,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $434 | $727,846884 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $92 | $246,425279 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $201 | $157,551223 claims |
| MerckDulera | $13 | $11,45618 claims |
| PfizerEliquis | $37 | $9,82116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Richmond
- Sujoy GillRichmond$296K
- Patricia SimeRichmond$113K
- Shilpa JohriRichmond$37K
- Apostolos PerelasRichmond$31K
- John SentzRichmond$20K
- Glenn GiesselRichmond$14K
- Nauman ChaudaryRichmond$13K
- Michael MistrettaRichmond$13K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.